CONTACT
+91 80 2808 2808
info@biocon.com
Inside banner
Biocon  /  News  /  Media Stories

MEDIA STORIES

Expect regulatory nods for deal with Serum and Viatris to come by H2: Kiran Mazumdar-Shaw, chairperson, Biocon and Biocon Biologics

04-May-2022

external_link-01
Biocon Biologics may close $3.34 billion Viatris deal in Q1

02-May-2022

external_link-01
Eyeing over 15% market share in US for insulin Glargine: Shreehas Tambe

30-April-2022

external_link-01
Biocon Biologics expects R&D expenses to hover between 10-15% in the next financial year

29-April-2022

external_link-01
Biocon arm to buy US company Biosimilar biz for $3.34 billion

01-Mar-2022

external_link-01
Biocon Biologics acquires Viatris for $3.33 billion

01-Mar-2022

external_link-01
Biocon Biologics acquires Viatris’ biosimilars business in $3.3 bn deal

28-Feb-2022

external_link-01
R&D expenditure will rise in the coming quarters: Biocon Biologics MD

25-Jan-2022

external_link-01
Insulins access program for young expanded in Dec quarter: Biocon Biologics MD

24-Jan-2022

external_link-01
Biocon Biologics set to reap biosimilar insulin glargine opportunity in US

22-Jan-2022

external_link-01
The Medicine Box: Kiran Mazumdar-Shaw on biosimilar interchangeable status for Biocon’s diabetes drug

25-Nov-2021

external_link-01
Biocon Biologics, Viatris confirm offering steep savings on long-acting insulin through Walgreens Prescription Savings Club

19-Nov-2021

external_link-01
Walgreens to sell Biocon’s insulin Semglee in the U.S.

19-Nov-2021

external_link-01
Biocon Biologics, Viatris launch interchangeable insulin biosimilar for US

 16-Nov-2021

external_link-01
Biocon starts campaign to treat diabetic children, train healthcare workers

 15-Nov-2021

external_link-01
Access to diabetes care: If not now, then when?

 14-Nov-2021

external_link-01
Biocon Rating: Hold – Vaccines to complement biosimilar portfolio

 20-Sep-2021

external_link-01
Biocon Biologics, Serum Institute Life Sciences announce strategic alliance

 20-Sep-2021

external_link-01
Biocon jumps into vaccines through $4.9bn Serum Institute pact

 20-Sep-2021

external_link-01
Can Serum deal provide a booster dose to Biocon’s target price?

 20-Sep-2021

external_link-01
Interchangeable insulin to help us compete with big insulin makers: Kiran Mazumdar-Shaw

 29-Aug-2021

external_link-01
Vaccines alone will not protect and make the world safer: Biocon chief

 30-Jul-2021

external_link-01
India must use, share Covid data transparently: Kiran Mazumdar-Shaw

 26-Jul-2021

external_link-01
Biocon partners Adagio for licence to make Covid-19 antibody cocktail

 26-Jul-2021

external_link-01
Biocon eyes market share expansion in developed, emerging markets: Kiran Mazumdar-Shaw

 23-Jul-2021

external_link-01
Biocon Q4 profit more than doubles to Rs 254 crore

 29-Apr-2021

external_link-01
Shreehas Tambe named Deputy CEO of Biocon Biologics

 02-Mar-2021

external_link-01
Biocon Biologics, Viatris get CHMP nod for Abevmy

 02-Mar-2021

external_link-01